CPC A61K 35/35 (2013.01) [A61K 35/12 (2013.01); A61K 35/14 (2013.01); A61K 35/19 (2013.01); A61K 35/33 (2013.01); A61K 35/34 (2013.01); A61K 38/1709 (2013.01); A61P 3/00 (2018.01); C12N 15/87 (2013.01); G01N 33/15 (2013.01); A61K 9/0029 (2013.01)] | 27 Claims |
1. A method of enhancing metabolic function of a target cell or tissue, comprising delivering to the target cell or tissue a pharmaceutical composition comprising isolated chondrisomes derived from cultured cells, wherein the pharmaceutical composition is produced by a method comprising:
(a) providing a cell culture;
(b) dissociating the cells of the cell culture to produce a subcellular composition, wherein the dissociating comprises applying to the cells of the cell culture a first shear force followed by a second, higher shear force;
(c) separating the subcellular composition into a cellular debris fraction and a chondrisome enriched fraction, wherein the separating comprises comprising carrying out a first centrifugation and a second centrifugation, a fluid fraction produced by the first centrifugation is subjected to the second centrifugation, the cellular debris fraction is a solid or pelleted fraction produced by the second centrifugation, and the chondrisome enriched fraction is a fluid fraction produced by the second centrifugation;
(d) separating the chondrisome enriched fraction produced by the second centrifugation into a fraction containing chondrisomes and a fraction substantially lacking chondrisomes, wherein separating comprises carrying out a third centrifugation and a fourth centrifugation, a solid or pelleted fraction produced by the third centrifugation is subjected to the fourth centrifugation, the fraction containing chondrisomes is a solid or pellet fraction produced by the fourth centrifugation, and the fraction lacking chondrisomes is a fluid fraction produced by the fourth centrifugation; and
(e) suspending the fraction containing chondrisomes in a solution, thereby preparing a chondrisome preparation;
wherein the composition is delivered to the target cell or tissue in-vivo in a human subject; and
wherein the composition: (i) decreases serum cholesterol levels and/or triglycerides in the subject, or (ii) increases cardiac function in the subject.
|